2026年6月最新影响因子数据已更新,欢迎查询使用。如果您对期刊系统有任何需求或者问题,欢迎反馈给我们。
![]() |
体验更多LetPub AI科研工具 >> | |
| 近期推荐: | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 | 新 已发表SCI?是时候来Springer出书了! |
| |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字![]() | MOLECULAR CANCER THERAPEUTICS MOL CANCER THER (此期刊被最新的JCR期刊SCIE收录) LetPub评分 7.7
54人评分
我要评分
声誉 8.6 影响力 6.6 速度 9.3 | |||||||||||||||||||||
| 期刊ISSN | 1535-7163 | 安装APP,查看期刊最新消息
| ||||||||||||||||||||
| E-ISSN | 1538-8514 | |||||||||||||||||||||
| 2025-2026最新IF (数据来源于网友提供) | 注册或登录后,查看IF | |||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日:6.4 | |||||||||||||||||||||
| 2025-2026自引率 | 1.4%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年IF (数据来源于网友提供) | 6.395数据由网友[泽雪澜]收集提供 | |||||||||||||||||||||
| h-index | 157 | |||||||||||||||||||||
| CiteScore ( 2026年6月最新版) |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://mct.aacrjournals.org/ | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | http://mct.msubmit.net/cgi-bin/main.plex | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | The Role of Siglec-15 in Tumor Immunity: Mechanisms and Therapy Author: Li, Lin; Wang, Li; Liu, Qin; Ye, Yingchun; Lei, Qian; Li, Chengwen; Guo, Xiyuan; Nian, Siji; Yuan, Qing Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 717-726. DOI: 10.1158/1535-7163.MCT-25-0323 IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer Author: Leslie, Amy R.; Ning, Shu; Sharifi, Masuda; Schaaf, Zachary A.; Maine, James P.; Lou, Wei; Leslie, Kristina D.; Liu, Chengfei; Xu, Hongyu; Lombard, Alan P.; Chen, Hong-Wu; Parikh, Mamta; Dall'Era, Marc; Gao, Allen C Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 786-798. DOI: 10.1158/1535-7163.MCT-25-0644 Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity Author: Du, Sicheng; Zhang, Ying; Hao, Ruidong; Qiu, Lupeng; Li, Chao; Li, Yuting; Liu, Rong-Rui; Zhao, Chuan-Hua; Li, Juan; Ye, Sisi; Zhou, Jun; Li, Yantao; Yi, Qiaoyong; Zhang, Shuangshuang; Sun, Minmin; Luo, Tianhang; Xu, Jianming Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 701-716. DOI: 10.1158/1535-7163.MCT-25-0171 MCT8 Modulates Metabolite Uptake and T-cell Exhaustion to Promote Immunosuppression and Tumor Progression in Hepatocellular Carcinoma Author: Bi, Bin; Tang, Liqin; Liang, Ranxi; Wu, Haijing; Huang, Qilan; Pan, Li Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 771-785. DOI: 10.1158/1535-7163.MCT-25-0564 | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足MOLECULAR CANCER THERAPEUTICS的语言要求,还能让MOLECULAR CANCER THERAPEUTICS编辑和审稿人得到更好的审稿体验,让稿件最大限度地被MOLECULAR CANCER THERAPEUTICS编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢(1篇) 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404 | |||||||||||||||||||||
| 出版商 | American Association for Cancer Research Inc. | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||
| 出版年份 | 2001 | |||||||||||||||||||||
| 年文章数 | 154点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 36.23% | |||||||||||||||||||||
| 研究类文章占比: 文章 ÷(文章 + 综述) | 91.56% | |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版:不在预警名单中 2025年03月发布的2025版:不在预警名单中 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||
| 《新锐期刊分区表》 ( 2026年3月发布) | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 ( 2025年3月升级版) |
| |||||||||||||||||||||
| 期刊分区表 ( 2023年12月旧的升级版) |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1535-7163%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验: 平均3月 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验: 约50% | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在MOLECULAR CANCER THERAPEUTICS顺利发表。
快看看作者怎么说吧:服务好评 论文致谢(1篇) 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | The Role of Siglec-15 in Tumor Immunity: Mechanisms and Therapy Author: Li, Lin; Wang, Li; Liu, Qin; Ye, Yingchun; Lei, Qian; Li, Chengwen; Guo, Xiyuan; Nian, Siji; Yuan, Qing Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 717-726. DOI: 10.1158/1535-7163.MCT-25-0323 PubMed DOI |
| 2. | IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer Author: Leslie, Amy R.; Ning, Shu; Sharifi, Masuda; Schaaf, Zachary A.; Maine, James P.; Lou, Wei; Leslie, Kristina D.; Liu, Chengfei; Xu, Hongyu; Lombard, Alan P.; Chen, Hong-Wu; Parikh, Mamta; Dall'Era, Marc; Gao, Allen C Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 786-798. DOI: 10.1158/1535-7163.MCT-25-0644 PubMed DOI |
| 3. | Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity Author: Du, Sicheng; Zhang, Ying; Hao, Ruidong; Qiu, Lupeng; Li, Chao; Li, Yuting; Liu, Rong-Rui; Zhao, Chuan-Hua; Li, Juan; Ye, Sisi; Zhou, Jun; Li, Yantao; Yi, Qiaoyong; Zhang, Shuangshuang; Sun, Minmin; Luo, Tianhang; Xu, Jianming Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 701-716. DOI: 10.1158/1535-7163.MCT-25-0171 PubMed DOI |
| 4. | MCT8 Modulates Metabolite Uptake and T-cell Exhaustion to Promote Immunosuppression and Tumor Progression in Hepatocellular Carcinoma Author: Bi, Bin; Tang, Liqin; Liang, Ranxi; Wu, Haijing; Huang, Qilan; Pan, Li Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 771-785. DOI: 10.1158/1535-7163.MCT-25-0564 DOI |
| 5. | HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate, Exerts Encouraging Antitumor Activities and Favorable Safety Profiles Author: Tian, Yunan; Zhang, Jieqiong; Sun, Xing; Yang, Changyong; Liao, Cheng Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 3, pp. 371-385. DOI: 10.1158/1535-7163.MCT-24-0680 PubMed DOI |
| 6. | Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistance Author: Pulido, Ines; Gunder, Laura C.; Ying, Chenghao; Wang, Yaya; Dai, Yan; Yang, Zimo; Rahnama, Alireza; Li, Jinhua; Sun, Yuetong; Liu, Chuhe; Zhou, Haoxin; Wang, Guoqiang; Foley, Kevin P.; Abdelhady, Khaled; Massad, Malek G.; Prince, Thomas L.; Papautsky, Ian; Ying, Weiwen; Shimamura, Takeshi Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 2, pp. 207-215. DOI: 10.1158/1535-7163.MCT-24-1173 PubMed DOI |
| 7. | SDP-LIV1, a Novel and Optimized LIV-1 Antibody-Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors Author: Peng, Yani; Yang, Changyong; Dong, Liwei; Sun, Xing; Zheng, Wei; Gong, Yanling; Shi, Qing; Ji, Ping; Chen, Simeng; Zhang, Wei; Liao, Cheng Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 2, pp. 322-332. DOI: 10.1158/1535-7163.MCT-24-0752 PubMed DOI |
| 8. | Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase-Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy Author: Niu, Dun; Zhang, Shaotong; Ma, Xiaozhuang; Wu, Yaran; Zhu, Junshi; Ran, Jianglang; Shan, Meihua; Dai, Xufang; Lu, Lu; Yang, Mingzhen; Lian, Jiqin Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 2, pp. 272-282. DOI: 10.1158/1535-7163.MCT-25-0356 PubMed DOI |
| 9. | A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism Author: Zhang, Huan; He, Fufan; Cao, Lei; Ni, Haiqing; Li, Ninghuan; Liu, Yang; Wu, Min; Liu, Ya; Wu, Bing; Li, Li; Wu, Zhihai; Ling, Xiaomin; Zhou, Shuaixiang; Li, Yiming; Deng, Shuxuan; Wu, Weiwei; Chu, Qian Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 1, pp. 21-33. DOI: 10.1158/1535-7163.MCT-25-0425 PubMed DOI |
| 10. | Targeting the ERα DBD-LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation Author: Wang, Han; Luo, Yuxuan; Artham, Sandeep; Wang, Qianqian; Peng, Yi; Yun, Zixi; Li, Xinyue; Wu, Chen; Liu, Zhenghao; Weber-Bonk, Kristen L.; Pai, Chun-Peng; Cao, Yuan; Yue, Jiangan; Park, Sunghee; Keri, Ruth A.; Geng, Lisheng; Mcdonnell, Donald P.; Kao, Hung-Ying; Yang, Sichun Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 1, pp. 107-124. DOI: 10.1158/1535-7163.MCT-25-0405 PubMed DOI |
|
|
|
投稿状态统计: 我要评分: | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范?试试稿件自查工具,一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验:共73条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号:沪ICP备10217908号-1
沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室